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Abstract: Introduction: Henoch-Schönlein Purpura (HSP) is a systemic IgA-mediated small-vessel vasculitis. It is 
primarily a childhood disease, rarely described in pregnancy. Pregnant women with HSP are at risk for hypertensive and 
hemorrhagic complications. Due to the rarity of the condition during pregnancy, there is no consensus about the 
preferred course of treatment but concerns regarding optimal management are ongoing.  
Case presentation: We report the case of an 18 year-old primigravida, with a 3-year history of HSP, who had an 
uneventful pregnancy and term delivery with epidural anesthesia.  
Conclusion: Due to the systemic nature of HSP, multidisciplinary management of pregnant HSP patients should be 
warranted to prevent complications.  
Keywords: Henoch-Schönlein purpura, Pregnancy, Medical complications, Epidural anesthesia, Nephritis, 
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INTRODUCTION 
Henoch-Schönlein Purpura (HSP) is a systemic IgA-
mediated small-vessel vasculitis. It is primarily a 
childhood disease [1-6], characterized by purpuric 
lesions on the lower limbs, episodic abdominal pain, 
arthritis, fever, malaise and glomerulonephritis with 
proteinuria and hematuria. Extra-renal manifestations 
include headaches, seizures and encephalopathy. 
Pregnant HSP patients are at risk of hypertensive 
complications, because of underlying nephropathy [1, 
2], and potentially of hemorrhagic complications. Risks 
of anesthesia complications might also be increased. 
CASE PRESENTATION 
An 18 year-old primigravida consulted for the first 
time in our maternity unit at 37 weeks of gestation. She 
was known for HSP diagnosed three years previously 
after an emergency hospitalization for gastritis, 
oligoarthritis, exanthema and palpable purpura. At that 
time, hepatic and renal functions were normal but 
hematuria and proteinuria were present. Colonoscopy 
showed diffuse lesions and ileal ulcers (Figures 1-4)  
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Figure 1 and 2: ileal edema and longitudinal fibrinous ulcers. 
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and the cutaneous biopsy showed IgA and C3infiltrates 
and signs of leukocytoclastic vasculitis. Renal biopsy 
showed severe IgA glomerulonephritis, with an 
extracapillary necrotizing component in 50% of 
glomeruli and endocapillary proliferation. The patient 
was treated with prednisone (40mg/day gradually 
reduced to 5mg every other day), azathioprine 
(50mg/day) and irbesartan (150mg/day) to prevent 
development of chronic kidney disease. Two years 
later, an HSP relapse occurred during an episode of 
viral gastro-enteritis. Acute renal insufficiency with pre-
renal component was present (creatinine 313umol/L, 
proteinuria 1.98g/24h and hematuria with glomerular 
erythrocytes) and the renal biopsy showed mesangial 
proliferative glomerulonephritis with signs of active and 
chronic lesions (Figures 5-6). She was treated with 
intravenous solumedrol 500mg/day for 3 days and 
irbesartan was suspended. At discharge, she was kept 
on prednisone (1 mg/Kg/day) and azathioprine (the 
latter being stopped 6 months later). 
 
Figure 5: (a) and (b) Mesangioproliferative glomerulone- 
phritis with numerous crescents (proliferative, necrotizing and 
crescentic glomerulonephritis). Trichrome staining. 
(b) (c) Immunofluorescence microscopy on frozen tissue for 
IgA with numerous mesangial deposits. 
 
Figure 3: sigmoidal lesions. 
 
Figure 4: rectal lesions. 
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Figure 6: (a) and (b) Mesangioproliferative glomerulone- 
phritis with fibrinoid necrosis. Trichrome staining. 
(b)(c) Immunofluorescence microscopy on formalin-fixed 
tissue for IgA with numerous mesangial 
deposits. 
Before conception, prednisone was tapered down to 
5mg/day and maintained at that dose during the 
pregnancy by her treating physicians. Renal function, 
blood pressure and urinary tests remained normal 
throughout the pregnancy. Fetal ultrasounds were 
normal with fetal growth within the 50
th
 percentile. Upon 
arrival at our maternity unit, a multidisciplinary meeting 
was convened to evaluate the risk of peripartum 
hemorrhage and anesthesia-related complications. The 
risks were considered to be low because HSP was in 
remission and there was no history of bleeding 
diathesis. Also, platelet count, prothrombin time, 
activated partial thromboplastin time as well as factor 
XIII level were in normal ranges. Fibrinogen and D-
dimers were increased, respectively at 4.7g/l (normal 
range 1.5-3.5) and 3099ng/ml (normal range 
<500ng/ml). 
The patient went into labor spontaneously at 38+5 
weeks and delivered a healthy, 3500g boy under 
epidural anesthesia. Peripartum blood loss was normal 
(estimated 300ml) and blood pressure remained within 
normal limits during labor and the postpartum period.  
DISCUSSION 
Clinical manifestations of HSP are due to IgA 
deposition in vessel walls and consequent small-vessel 
vasculitis. According to the American College of 
Rheumatology [7] two or more of the following criteria 
are required for the diagnosis of HSP: age younger 
than 20 years, palpable purpura, abdominal pain or 
gastrointestinal bleeding, extravascular or perivascular 
granulocytes on biopsy. The Chapel Hill Consensus 
Group requires only vasculitis of the small vessels with 
IgA deposition [8]. 
HSP has a favorable prognosis, particularly in 
pediatric patients. The condition is usually self-limited, 
with recurrences generally resolving with treatment 
after 4-6 months [3, 9]. Renal involvement, manifested 
by hematuria and less frequently proteinuria, is more 
common and severe in adults. Prognostic factors for 
chronic renal insufficiency are renal involvement at 
disease onset, severe abdominal pain and persistent 
purpura [9]. Nephritis can lead to chronic renal 
insufficiency but progression to end-stage renal 
disease is rare (1-3%).  
Pregnant woman with HSP are at higher risk of 
hypertensive complications, prompting to differential 
diagnosis with preeclampsia when proteinuria is 
present [2, 3]. As IgA immunoglobulins do not cross the 
placenta, fetal morbidity seems to be due to maternal 
renal and hypertensive complications rather than to 
HSP itself [2]. We found 20 cases of HSP in pregnancy 
reported in the literature. Nine were new cases 
diagnosed either during pregnancy (n=8) or post-
partum (n=1), and the remainders were relapses. In 6 
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relapse cases, pregnancy occurred during disease 
exacerbation and 2 of these experienced spontaneous 
remission during pregnancy [6, 10-12, 17]. 
Complications were frequent with only 8/20 having 
uncomplicated term deliveries. There were 4 cases of 
preterm delivery (one due to severe preeclampsia), 7 
cases of hypertensive complications (one also preterm 
and one with pregnancy termination at 24 weeks) and 2 
fetal deaths (at 20 and 25 weeks) [12, 13]. 
In a cohort of 116 pregnancies in women with IgA 
nephritis, glomerulonephritis was associated with a 
greater incidence of obstetrical complications 
(hypertension, preeclampsia, intrauterine growth 
retardation and fetal loss) when proliferative lesions 
were present [14]. In a review of 22 pregnancies 
complicated by non-HSP IgA nephropathy, unfavorable 
pregnancy outcome was correlated with the degree of 
hypertension and renal insufficiency. In this study, over 
half of pregnancies were complicated with 
hypertension, proteinuria or both. When hypertension 
or proteinuria were present, the risk of preterm delivery 
was 30% [15]. We might hypothesize that pregnant 
women with HSP are also at higher risk for obstetrical 
complications if there is renal involvement or 
hypertension, as happens in women with IgA nephritis.  
Regarding the effect of pregnancy on renal 
involvement in HSP patients, one study showed 
irreversible deterioration of renal function, possibly due 
to hyperfiltration during pregnancy [16]. Therefore, 
renal function should be monitored during pregnancy.  
Standard coagulation tests, including platelet count, 
are usually normal in HSP patients but some reports 
suggest the presence of coagulation activation and 
hyperfibrinolysis. Plasma levels of factor XIII were 
decreased in some cases [17-19], whereas D-dimers 
were usually elevated without criteria for disseminated 
intravascular coagulation. Also, Von Willebrand factor 
was found abnormally high with presence of abnormal 
large multimers of von Willebrand factor, reflecting 
damage to endothelial cells [18]. It is not clear if the 
anomalies in coagulation factors (specially decrease of 
factor XIII levels) and fibrinolysis might play a role in 
the physiopathology of the bleeding complications 
observed in HSP. However, the main reason for this is 
the presence of vasculitis.  
The literature regarding pain management and 
neuraxial anesthesia in HSP patients is scarce [1, 25]. 
Many experts suggest that if there is no evidence of 
active HSP, no history of bleeding diathesis and if the 
platelet count is normal, neuraxial blocks should not be 
contraindicated [1, 25]. Some teams are nevertheless 
concerned about the risk of epidural hematoma due to 
altered coagulation and fibrinolysis and choose to 
manage pain with intravenous opioids [1]. Pregnant 
patients with HSP should be referred early to the 
anesthesia team to assess the risk and benefit of 
neuraxial block and discuss alternative strategies in 
case of contraindication. 
Regarding treatment, no consensus has yet been 
reached, even in the non-pregnant population. Oral 
corticosteroids could be beneficial, decreasing duration 
and severity of abdominal pain and joint symptoms and 
hastening resolution of mild HSP nephritis. Steroids do 
not, however, prevent renal complications, treat 
purpura, shorten the duration of disease or prevent 
recurrences [3, 9, 17, 21]. Some authors suggested 
treating only patients with risk factors for renal 
involvement at disease onset [18, 22]. Prednisone is 
often favored over methylprednisolone during 
pregnancy, as transplacental passage occurs in small 
amounts, reducing the risk of fetal adverse effects [2, 
23]. Among the 20 cases of HSP during pregnancy, 
half were treated with steroids, leading to rapid 
resolution of purpura, abdominal symptoms or 
arthralgia [6]. Plasmapheresis was effectively used in 
one relapse case [24]. Hemodialysis was successfully 
used in one case where HSP was diagnosed at 23 
weeks gestation and hypertension, anasarca and renal 
failure appeared at 32 weeks [6].  
CONCLUSION 
HSP during pregnancy is rare but the systemic 
nature of the disease has the potential to cause severe 
renal, hypertensive and hemorrhagic complications. 
Patients should be referred early to a high-risk 
pregnancy unit in to warrant multidisciplinary follow-up.  
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